Histone deacetylases (HDAC) are emerging as promising targets in cancer, neuronal diseases and immune disorders. Computational modelling approaches have been widely applied for the virtual screening and rational design of novel HDAC inhibitors. In this study, different machine learning (ML) techniques were applied for the development of models that accurately discriminate HDAC2 inhibitors form non-inhibitors. The obtained models showed encouraging results, with the global accuracy in the external set ranging from 0.83 to 0.90. Various aspects related to the comparison of modelling techniques, applicability domain and descriptor interpretations were discussed. Finally, consensus predictions of these models were used for screening HDAC2 inhibitors from four chemical libraries whose bioactivities against HDAC1, HDAC3, HDAC6 and HDAC8 have been known. According to the results of virtual screening assays, structures of some hits with pair-isoform-selective activity (between HDAC2 and other HDACs) were revealed. This study illustrates the power of ML-based QSAR approaches for the screening and discovery of potent, isoform-selective HDACIs.

Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors

Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries

Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors

Citations

Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries

Related Papers (5)

Computational identification of novel histone deacetylase inhibitors by docking based QSAR

Docking-based 3D-QSAR Studies of Phosphodiesterase 9A Inhibitors

3D-QSAR Studies of VEGFR-2 Kinase Inhibitors Based on Docking

3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors

Cytotoxicity Activity Model of Hydroxamic Acid Analogues as Histone Deacetylase (hdac) Inhibitors Based on Docking and Pharmacophore 3D QSAR Approach